Cyclacel Pharmaceuticals (CYCC) AI Stock Analysis

• Market Cap: $20.70M
• Dividend Yield: N/A
• Average Volume (3M): 3.40M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: -89.76%
• EPS Growth: 80.28%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 1,583,965
• 10 Day Avg. Volume: 9,734,248
• 30 Day Avg. Volume: 3,403,940
• PEG Ratio: -0.12
• Price to Book (P/B): 14.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.47
• Enterprise Value/Market Cap: 3.63
• Enterprise Value/Revenue: 533.35
• Enterprise Value/Gross Profit: -2.79K
• Enterprise Value/Ebitda: -1.24
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 38 Underperform
• Price Target: ―

Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.

Cyclacel Pharmaceuticals Business Overview & Revenue Model

Company Description

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

How the Company Makes Money

Cyclacel Pharmaceuticals generates revenue primarily through the development and commercialization of its proprietary cancer therapies. The company’s revenue model is centered around licensing agreements, collaborations, and strategic partnerships with other pharmaceutical companies. These agreements often include upfront payments, milestone payments, and royalties on sales of successfully developed products. Additionally, Cyclacel may receive funding from government grants and research collaborations, which support their clinical trials and research initiatives. As a clinical-stage company, significant revenue generation typically occurs post-commercialization of their drug candidates.

Cyclacel Pharmaceuticals Financial Statement Overview

Summary

Cyclacel Pharmaceuticals is facing significant financial challenges, characterized by operational losses, negative cash flows, and a weak balance sheet. The company needs to improve operational efficiency and stabilize its financial position to enhance investor confidence.

Income Statement

Cyclacel Pharmaceuticals has exhibited a volatile revenue pattern with recent growth from a low base. The gross profit margin is 100% due to low revenue, while the net profit margin remains negative due to significant losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet indicates high leverage with negative stockholders' equity, suggesting financial instability. The equity ratio is negative, and the company has no debt, which is positive, but high liabilities limit flexibility. Return on equity is not meaningful due to negative equity.

Cash Flow

The company has consistently reported negative free cash flow, indicating challenges in generating cash from operations. The operating cash flow to net income ratio is negative, highlighting inefficiencies in cash conversion.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	43.00K	420.00K	0.00	0.00	0.00
Gross Profit	37.00K	420.00K	-32.00K	-43.00K	-20.00K
EBITDA	-12.00M	-25.42M	-27.62M	-22.69M	-10.62M
Net Income	-11.21M	-22.55M	-21.20M	-18.89M	-8.45M
Balance Sheet
Total Assets	4.09M	8.80M	28.05M	42.59M	36.80M
Cash, Cash Equivalents and Short-Term Investments	3.14M	3.38M	18.34M	36.56M	33.41M
Total Debt	0.00	37.00K	106.00K	30.00K	1.06M
Total Liabilities	6.27M	8.20M	7.62M	5.44M	3.54M
Stockholders Equity	-2.17M	607.00K	20.43M	37.69M	33.26M
Cash Flow
Free Cash Flow	-7.99M	-16.12M	-20.83M	-18.57M	-8.03M
Operating Cash Flow	-7.99M	-16.11M	-20.83M	-18.54M	-7.93M
Investing Cash Flow	0.00	-6.00K	-7.00K	-27.00K	-96.00K
Financing Cash Flow	7.82M	848.00K	3.00M	21.74M	29.50M

Cyclacel Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 13.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYCC, the sentiment is Neutral. The current price of 13.07 is above the 20-day moving average (MA) of 5.60, below the 50-day MA of 17.27, and below the 200-day MA of 81.62, indicating a neutral trend. The MACD of -1.89 indicates Negative momentum. The RSI at 57.35 is Neutral, neither overbought nor oversold. The STOCH value of 41.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CYCC.

Cyclacel Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVTX	54 Neutral	$67.67M	―	678.24%	―	-69.59%	―
Sector *	52 Neutral	$7.35B	-0.07	-63.71%	2.81%	16.17%	0.03%
KPTI	42 Neutral	$33.26M	―	41.08%	―	1.19%	61.65%
IKNA	41 Neutral	$61.29M	―	-30.49%	―	-100.00%	37.59%
APLT	39 Underperform	$65.39M	―	-83.71%	―	―	―
CYCC	38 Underperform	$20.70M	―	-1949.77%	―	-89.76%	80.28%
PRLD	35 Underperform	$45.45M	―	-81.44%	―	―	16.38%

Cyclacel Pharmaceuticals Corporate Events

Cyclacel Pharmaceuticals Appoints New Directors Amid Strategic Shift

On March 31, 2025, Cyclacel Pharmaceuticals announced the delayed resignation of its co-principal financial officer, David Lazar, and two independent directors, Avraham Ben-Tzvi and David Natan, until the filing of the company’s annual report. Subsequently, on April 2, 2025, the company appointed two new independent directors, Ms. Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan, to its board. The company also reported financial results for the fourth quarter, highlighting a strategic focus on developing plogosertib, a PLK1 inhibitor for advanced cancers, and the liquidation of its subsidiary, Cyclacel Limited, which is expected to reduce research and development expenses and increase stockholders’ equity by approximately $5 million.

Cyclacel Pharmaceuticals Announces New Leadership and Restructuring

On February 26, 2025, Cyclacel Pharmaceuticals announced a significant change in control and leadership following the completion of a Securities Purchase Agreement. Datuk Dr. Doris Wong Sing Ee acquired a controlling interest in Cyclacel, becoming the new CEO and Executive Director, while Kiu Cu Seng was appointed as the Chief Financial Officer. This transition marks a strategic shift for Cyclacel, potentially impacting its operations and market positioning. The company also experienced several board resignations and new appointments, indicating a broader restructuring effort.